Nintedanib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally 150 mg twice daily (morning and evening), approximately 12 hours apart strictly WITH FOOD with a full glass of water. Swallow capsules whole; do NOT chew or crush to avoid bitter taste and esophageal irritation.
⚠️ Side Effects
Common: Diarrhea (occurs in >60% of patients), nausea, abdominal pain, vomiting, weight loss, elevated liver enzymes (ALT, AST, alkaline phosphatase). Rare/Severe: Drug-induced liver injury / jaundice, arterial thromboembolism, gastrointestinal perforation, and severe bleeding.
🛡️ Safety Warnings
Black Box Warning: Embryofetal toxicity (Category X); strict contraception required. Monitor liver function tests (ALT, AST, bilirubin) prior to initiation, monthly for the first 3 months, and periodically thereafter. Manage diarrhea immediately with hydration and loperamide.
Jan Aushadhi Products containing Nintedanib
Found 2 generic formulation(s) containing this active ingredient.
Nintedanib Soft gelatin Capsules 150mg
Nintedanib Soft Gelatin Capsules (100mg, 150mg) is an oral triple angiokinase inhibitor that targets receptor tyrosine kinases for vascular endothelial growth factor (VEGFR-1/2/3), fibroblast growth factor (FGFR-1/2/3), and platelet-derived growth factor (PDGFR-alpha/beta). In pulmonary fibrosis, it inhibits proliferation, migration, and transformation of lung fibroblasts into myofibroblasts, slowing the rate of pulmonary function decline (FVC loss). Indicated for Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung diseases with a progressive phenotype, systemic sclerosis-associated ILD, and in combination with docetaxel for advanced NSCLC of adenocarcinoma histology.
Nintedanib Soft Gelatin Capsules 100mg
Nintedanib Soft Gelatin Capsules (100mg, 150mg) is an oral triple angiokinase inhibitor that targets receptor tyrosine kinases for vascular endothelial growth factor (VEGFR-1/2/3), fibroblast growth factor (FGFR-1/2/3), and platelet-derived growth factor (PDGFR-alpha/beta). In pulmonary fibrosis, it inhibits proliferation, migration, and transformation of lung fibroblasts into myofibroblasts, slowing the rate of pulmonary function decline (FVC loss). Indicated for Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung diseases with a progressive phenotype, systemic sclerosis-associated ILD, and in combination with docetaxel for advanced NSCLC of adenocarcinoma histology.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Nintedanib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Nintedanib Soft gelatin Capsules 150mg | 10's | ₹399.84 | Macdanib, Mantedanib | ₹843.56 | 53% Save |
| Nintedanib Soft Gelatin Capsules 100mg | 10's | ₹499.69 | Mantedanib, NIntabID | ₹776.00 | 36% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Nintedanib generics.